Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model  Arnd S Boehle, MD, Bence Sipos, MD, Ursula.

Published byIndra Halim Modified over 5 years ago

Similar presentations

Presentation on theme: "Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model  Arnd S Boehle, MD, Bence Sipos, MD, Ursula."— Presentation transcript:

1 Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model  Arnd S Boehle, MD, Bence Sipos, MD, Ursula Kliche, Holger Kalthoff, PhD, Peter Dohrmann, PhD  The Annals of Thoracic Surgery  Volume 71, Issue 5, Pages (May 2001) DOI: /S (01) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 H3-Thymidine incorporation assay. (A) Three hours of exposure to 10−4 mol/L CA-4PD induced in KNS-62 a 37% inhibition of proliferation; in Colo-699 this concentration inhibited proliferation by 69% (∗∗ p < 0.01; bars, SD). (B) Prolongation of drug exposure to 24 hours augmented the antiproliferative effect of CA-4PD on human lung cancer cells; a 10−8 mol/L concentration was effective in reducing proliferation by 49% and 59%, respectively (∗∗ p < 0.01; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Cell viability assay. (A) Three hours of exposure to 10−4 mol/L CA-4PD reduced cell viability in KNS-62 by 31% (∗∗ p < 0.01). In Colo-699, 10−5 mol/L CA-4PD reduced cell viability by 21% (∗ p < 0.05; bars, SD). (B) Prolongation of CA-4PD exposure increased the cytotoxic effect; 10−8 mol/L effected significant reductions in cell viability for both cell lines (∗ p < 0.05; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Tumor volume after subcutaneous xenotransplantation of human adenocarcinoma (Colo-699) of the lung. After subcutaneous xenotransplantation of Colo-699 the average tumor volume measured 100 mm3 on day 23, when intraperitoneal application of 50 mg/kg CA-4PD for 21 days was started (arrow). Tumors in control animals continued exponential growth, whereas systemic application of CA-4PD delayed tumor growth significantly (∗∗ p < 0.01; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Tumor volume after subcutaneous xenotransplantation of human squamous cell carcinoma (KNS-62) of the lung. After subcutaneous xenotransplantation of KNS-62 the average tumor volume measured 100 mm3 on day 17, when intraperitoneal application of 50 mg/kg CA-4PD for 21 days was started (arrow). Systemic application of CA-4PD induced a significant growth delay in subcutaneously induced human squamous cell carcinoma (∗ p < 0.05; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 Microvessel count did not differ significantly between treated tumors and untreated controls (MVD = microvessel density; n.s. = not significant). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

7 Fig 6 Systemic application of CA-4PD induced marked rise of VEGF and bFGF staining indices in comparison to untreated controls (n.s. = not significant; bFGF = basic fibroblast growth factor; VEGF = vascular endothelial growth factor; ∗ p < 0.05; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

8 Fig 7 Systemic treatment by CA-4PD markedly reduces the proportion of proliferating tumor cells (∗∗ p < 0.01; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

9 Fig 8 The fraction of apoptotic cells is not significantly altered by systemic CA-4PD application (n.s. = not significant; ∗ p < 0.05; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

10 Fig 9 Magnetic resonance image 21 days after orthotopic tumor induction. At the site of tumor induction in the upper left lung a prominent tumor developed, penetrating the thoracic wall and infiltrating the subcutaneous fat tissue, thereby lifting the left extremity. The lungs are surrounded by malignant pleural effusions in both pleural cavities subsequent to the growth of metastasis in the mediastinum and both pleural cavities. The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

11 Fig 10 Experimental animal survival after intrapulmonary tumor induction. Systemic application of 50 mg/kg CA-4PD prolonged animal survival after xenotransplantation of a human adenocarcinoma of the lung (Colo-699) by 29%. After xenotransplantation of a human squamous cell carcinoma of the lung (KNS-62), survival was prolonged by 35%. (∗ p < 0.05; ∗∗ p < 0.01; bars, SD). The Annals of Thoracic Surgery  , DOI: ( /S (01) ) Copyright © 2001 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model  Arnd S Boehle, MD, Bence Sipos, MD, Ursula."

Similar presentations

Volume 114, Issue 6, Pages (December 1998)

Volume 114, Issue 6, Pages (December 1998)
A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,
Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 

Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.
Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model  Mari Fukunaga, MD, Shinzo Takamori, MD, Akihiro Hayashi,

Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model  Mari Fukunaga, MD, Shinzo Takamori, MD, Akihiro Hayashi,
Kaviyanka Selvasandran, MS, Georges Makhoul, MD, MS, Prashant K

Kaviyanka Selvasandran, MS, Georges Makhoul, MD, MS, Prashant K
Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy  Mir Alireza Hoda, MD, Amir Mohamed, BSc,

Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy  Mir Alireza Hoda, MD, Amir Mohamed, BSc,
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.

NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.
An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice  Arnd S Boehle, MD, Peter Dohrmann, PhD, Ivo Leuschner, MD, Holger.

An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice  Arnd S Boehle, MD, Peter Dohrmann, PhD, Ivo Leuschner, MD, Holger.
Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell.

Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.
Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A
Rapamycin is an effective inhibitor of human renal cancer metastasis1

Rapamycin is an effective inhibitor of human renal cancer metastasis1
Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 

Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
Collision Tumor of Esophagus: Report of Three Cases

Collision Tumor of Esophagus: Report of Three Cases
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Similar presentations

Ads by Google